GlassScriptPhysician profile
Justin C Frey
NPI 1164708004
$623.25
in general payments reported to CMS, 2019-2025
14 companies · $19.10 in 2025
The $19.10 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $278 · 2022: $108 · 2023: $186 · 2024: $32.47 · 2025: $19.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $237.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $135.48 | 2022-2025 | Arexvy, Shingrix |
| Novo Nordisk INC | $127.74 | 2023 | Ozempic, Rybelsus, Saxenda |
| Pfizer INC. | $101.24 | 2019-2022 | |
| Lilly USA, LLC | $56.19 | 2019-2023 | Mounjaro |
| Merck Sharp & Dohme LLC | $35.82 | 2019-2024 | M-M-R II, Gardasil 9, Gardasil |
| Janssen Pharmaceuticals, INC | $33.17 | 2019 | |
| Sanofi-Aventis U.S. LLC | $21.38 | 2019 | |
| Supernus Pharmaceuticals, INC. | $21.00 | 2019 | |
| Shire North American Group INC | $18.89 | 2019 | |
| Exact Sciences Corporation | $17.41 | 2023 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $17.28 | 2019 | |
| Idorsia Pharmaceuticals US INC | $13.20 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.47 | 2019 | |
| Scilex Pharmaceuticals INC. | $11.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Frey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.